BRUKINSA demonstrated superiority in progression-free survival over chemoimmunotherapy as a first-line treatment for patients with chronic lymphocytic leukemia Consistent efficacy was observed across high-risk patient subgroups Safety results were generally ...
- Pooled study results showed significantly higher graft-versus-host disease-free, relapse-free survival rates and improved overall survival rates with Orca-T compared to standard of care - Data from Phase 1b/2 trials ...
Oral presentation demonstrated rapid and sustained T cell and B cell recovery following transplantation with omidubicel in a subset of patients in Phase 3 study, providing mechanistic support for reducing ...
Oral presentation at 63rd American Society of Hematology Annual Meeting includes results from the HERACLES Phase 2 trial in 24 patients with steroid-resistant Grade III-IV gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) ...
Of the 23 high-risk allogeneic hematopoietic cell transplant patients in this analysis, no end-organ viral disease was observed Of the 13 patients who completed through the Week 14 primary endpoint, ...
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, ...
Copyright © 2015 - 2021 Lifecarenews.in
